- Home
- SPHR vs DNTH Comparison
SPHR vs DNTH Comparison
Compare SPHR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHR
- DNTH
- Stock Information
- Founded
- SPHR 2020
- DNTH 2015
- Country
- SPHR United States
- DNTH United States
- Employees
- SPHR N/A
- DNTH N/A
- Industry
- SPHR Services-Misc. Amusement & Recreation
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- SPHR Consumer Discretionary
- DNTH Health Care
- Exchange
- SPHR Nasdaq
- DNTH Nasdaq
- Market Cap
- SPHR 1.7B
- DNTH 1.5B
- IPO Year
- SPHR N/A
- DNTH N/A
- Fundamental
- Price
- SPHR $59.46
- DNTH $37.47
- Analyst Decision
- SPHR Buy
- DNTH Strong Buy
- Analyst Count
- SPHR 9
- DNTH 9
- Target Price
- SPHR $51.22
- DNTH $61.57
- AVG Volume (30 Days)
- SPHR 1.3M
- DNTH 987.2K
- Earning Date
- SPHR 11-11-2025
- DNTH 11-06-2025
- Dividend Yield
- SPHR N/A
- DNTH N/A
- EPS Growth
- SPHR N/A
- DNTH N/A
- EPS
- SPHR N/A
- DNTH N/A
- Revenue
- SPHR $1,040,932,000.00
- DNTH $4,854,000.00
- Revenue This Year
- SPHR $9.57
- DNTH N/A
- Revenue Next Year
- SPHR $9.62
- DNTH N/A
- P/E Ratio
- SPHR N/A
- DNTH N/A
- Revenue Growth
- SPHR 1.37
- DNTH 17.87
- 52 Week Low
- SPHR $23.89
- DNTH $13.37
- 52 Week High
- SPHR $61.28
- DNTH $38.59
- Technical
- Relative Strength Index (RSI)
- SPHR 75.57
- DNTH 83.36
- Support Level
- SPHR $51.35
- DNTH $36.00
- Resistance Level
- SPHR $61.28
- DNTH $24.81
- Average True Range (ATR)
- SPHR 2.65
- DNTH 2.71
- MACD
- SPHR 1.35
- DNTH 1.15
- Stochastic Oscillator
- SPHR 90.09
- DNTH 92.90
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.